-
1
-
-
0036678472
-
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
-
Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L., and Van Etten R.A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA 99 (2002) 10700-10705
-
(2002)
Proc. Natl. Acad. Sci. USA
, vol.99
, pp. 10700-10705
-
-
Roumiantsev, S.1
Shah, N.P.2
Gorre, M.E.3
Nicoll, J.4
Brasher, B.B.5
Sawyers, C.L.6
Van Etten, R.A.7
-
2
-
-
20844448396
-
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
-
Tamborini E., Bonadiman L., Greco A., Albertini V., Negri T., Gronchi A., Bertulli R., Colecchia M., Casali P.G., Pierotti M.A., and Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127 (2004) 294-299
-
(2004)
Gastroenterology
, vol.127
, pp. 294-299
-
-
Tamborini, E.1
Bonadiman, L.2
Greco, A.3
Albertini, V.4
Negri, T.5
Gronchi, A.6
Bertulli, R.7
Colecchia, M.8
Casali, P.G.9
Pierotti, M.A.10
Pilotti, S.11
-
3
-
-
20444459499
-
The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy
-
Dowell J.E., and Minna J.D. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nat. Clin. Pract. Oncol. 1 (2004) 2-3
-
(2004)
Nat. Clin. Pract. Oncol.
, vol.1
, pp. 2-3
-
-
Dowell, J.E.1
Minna, J.D.2
-
4
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
Riely, G.J.4
Somwar, R.5
Zakowski, M.F.6
Kris, M.G.7
Varmus, H.8
-
5
-
-
0035573938
-
Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors
-
Haddad R., Lipson K.E., and Webb C.P. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res. 21 (2001) 4243-4252
-
(2001)
Anticancer Res.
, vol.21
, pp. 4243-4252
-
-
Haddad, R.1
Lipson, K.E.2
Webb, C.P.3
-
6
-
-
0345601083
-
Met, metastasis, motility and more
-
Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 4 (2003) 915-925
-
(2003)
Nat. Rev. Mol. Cell. Biol.
, vol.4
, pp. 915-925
-
-
Birchmeier, C.1
Birchmeier, W.2
Gherardi, E.3
Vande Woude, G.F.4
-
7
-
-
0036221263
-
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
-
Danilkovitch-Miagkova A., and Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109 (2002) 863-867
-
(2002)
J. Clin. Invest.
, vol.109
, pp. 863-867
-
-
Danilkovitch-Miagkova, A.1
Zbar, B.2
-
8
-
-
1342321789
-
Targeting c-Kit mutations: basic science to novel therapies
-
Sattler M., and Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leukemia Res. 28 Suppl. 1 (2004) S11-20
-
(2004)
Leukemia Res.
, vol.28
, Issue.SUPPL. 1
-
-
Sattler, M.1
Salgia, R.2
-
9
-
-
31544482729
-
Functional Analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
-
Jagadeeswaran R., Ma P.C., Seiwert T.Y., Jagadeeswaran S., Zumba O., Nallasura V., Ahmed S., Filiberti R., Paganuzzi M., Puntoni R., Kratzke R.A., Gordon G.J., Sugarbaker D.J., Bueno R., Janamanchi V., Bindokas V.P., Kindler H.L., and Salgia R. Functional Analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66 (2006) 352-361
-
(2006)
Cancer Res.
, vol.66
, pp. 352-361
-
-
Jagadeeswaran, R.1
Ma, P.C.2
Seiwert, T.Y.3
Jagadeeswaran, S.4
Zumba, O.5
Nallasura, V.6
Ahmed, S.7
Filiberti, R.8
Paganuzzi, M.9
Puntoni, R.10
Kratzke, R.A.11
Gordon, G.J.12
Sugarbaker, D.J.13
Bueno, R.14
Janamanchi, V.15
Bindokas, V.P.16
Kindler, H.L.17
Salgia, R.18
-
10
-
-
17344381429
-
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
-
Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.C., Geil L., Orcutt M.L., Stackhouse T., Zbar B., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16 (1997) 68-73
-
(1997)
Nat. Genet.
, vol.16
, pp. 68-73
-
-
Schmidt, L.1
Duh, F.M.2
Chen, F.3
Kishida, T.4
Glenn, G.5
Choyke, P.6
Scherer, S.W.7
Zhuang, Z.8
Lubensky, I.9
Dean, M.10
Allikmets, R.11
Chidambaram, A.12
Bergerheim, U.R.13
Feltis, J.T.14
Casadevall, C.15
Zamarron, A.16
Bernues, M.17
Richard, S.18
Lips, C.J.19
Walther, M.M.20
Tsui, L.C.21
Geil, L.22
Orcutt, M.L.23
Stackhouse, T.24
Zbar, B.25
more..
-
11
-
-
0033535530
-
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
-
Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., Lubensky I., Neumann H.P., Brauch H., Decker J., Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U., Gerrard B., Dean M., Linehan W.M., and Zbar B. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18 (1999) 2343-2350
-
(1999)
Oncogene
, vol.18
, pp. 2343-2350
-
-
Schmidt, L.1
Junker, K.2
Nakaigawa, N.3
Kinjerski, T.4
Weirich, G.5
Miller, M.6
Lubensky, I.7
Neumann, H.P.8
Brauch, H.9
Decker, J.10
Vocke, C.11
Brown, J.A.12
Jenkins, R.13
Richard, S.14
Bergerheim, U.15
Gerrard, B.16
Dean, M.17
Linehan, W.M.18
Zbar, B.19
-
12
-
-
0034673699
-
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
-
Di Renzo M.F., Olivero M., Martone T., Maffe A., Maggiora P., Stefani A.D., Valente G., Giordano S., Cortesina G., and Comoglio P.M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19 (2000) 1547-1555
-
(2000)
Oncogene
, vol.19
, pp. 1547-1555
-
-
Di Renzo, M.F.1
Olivero, M.2
Martone, T.3
Maffe, A.4
Maggiora, P.5
Stefani, A.D.6
Valente, G.7
Giordano, S.8
Cortesina, G.9
Comoglio, P.M.10
-
13
-
-
0141988690
-
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
-
Ma P.C., Kijima T., Maulik G., Fox E.A., Sattler M., Griffin J.D., Johnson B.E., and Salgia R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63 (2003) 6272-6281
-
(2003)
Cancer Res.
, vol.63
, pp. 6272-6281
-
-
Ma, P.C.1
Kijima, T.2
Maulik, G.3
Fox, E.A.4
Sattler, M.5
Griffin, J.D.6
Johnson, B.E.7
Salgia, R.8
-
14
-
-
0346753584
-
Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx
-
Aebersold D.M., Landt O., Berthou S., Gruber G., Beer K.T., Greiner R.H., and Zimmer Y. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22 (2003) 8519-8523
-
(2003)
Oncogene
, vol.22
, pp. 8519-8523
-
-
Aebersold, D.M.1
Landt, O.2
Berthou, S.3
Gruber, G.4
Beer, K.T.5
Greiner, R.H.6
Zimmer, Y.7
-
15
-
-
0033950508
-
Different point mutations in the met oncogene elicit distinct biological properties
-
Giordano S., Maffe A., Williams T.A., Artigiani S., Gual P., Bardelli A., Basilico C., Michieli P., and Comoglio P.M. Different point mutations in the met oncogene elicit distinct biological properties. FASEB J. 14 (2000) 399-406
-
(2000)
FASEB J.
, vol.14
, pp. 399-406
-
-
Giordano, S.1
Maffe, A.2
Williams, T.A.3
Artigiani, S.4
Gual, P.5
Bardelli, A.6
Basilico, C.7
Michieli, P.8
Comoglio, P.M.9
-
16
-
-
10344220547
-
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele
-
Graveel C., Su Y., Koeman J., Wang L.M., Tessarollo L., Fiscella M., Birchmeier C., Swiatek P., Bronson R., and Vande Woude G. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc. Natl. Acad. Sci. USA 101 (2004) 17198-17203
-
(2004)
Proc. Natl. Acad. Sci. USA
, vol.101
, pp. 17198-17203
-
-
Graveel, C.1
Su, Y.2
Koeman, J.3
Wang, L.M.4
Tessarollo, L.5
Fiscella, M.6
Birchmeier, C.7
Swiatek, P.8
Bronson, R.9
Vande Woude, G.10
-
17
-
-
17144462419
-
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion
-
Wang X., Le P., Liang C., Chan J., Kiewlich D., Miller T., Harris D., Sun L., Rice A., Vasile S., Blake R.A., Howlett A.R., Patel N., McMahon G., and Lipson K.E. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol. Cancer Ther. 2 (2003) 1085-1092
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 1085-1092
-
-
Wang, X.1
Le, P.2
Liang, C.3
Chan, J.4
Kiewlich, D.5
Miller, T.6
Harris, D.7
Sun, L.8
Rice, A.9
Vasile, S.10
Blake, R.A.11
Howlett, A.R.12
Patel, N.13
McMahon, G.14
Lipson, K.E.15
-
18
-
-
0141481285
-
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase
-
Sattler M., Pride Y.B., Ma P., Gramlich J.L., Chu S.C., Quinnan L.A., Shirazian S., Liang C., Podar K., Christensen J.G., and Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63 (2003) 5462-5469
-
(2003)
Cancer Res.
, vol.63
, pp. 5462-5469
-
-
Sattler, M.1
Pride, Y.B.2
Ma, P.3
Gramlich, J.L.4
Chu, S.C.5
Quinnan, L.A.6
Shirazian, S.7
Liang, C.8
Podar, K.9
Christensen, J.G.10
Salgia, R.11
-
19
-
-
10744228765
-
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo
-
Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Le P., Chen J., Wang X., Ruslim L., Blake R., Lipson K.E., Ramphal J., Do S., Cui J.J., Cherrington J.M., and Mendel D.B. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63 (2003) 7345-7355
-
(2003)
Cancer Res.
, vol.63
, pp. 7345-7355
-
-
Christensen, J.G.1
Schreck, R.2
Burrows, J.3
Kuruganti, P.4
Chan, E.5
Le, P.6
Chen, J.7
Wang, X.8
Ruslim, L.9
Blake, R.10
Lipson, K.E.11
Ramphal, J.12
Do, S.13
Cui, J.J.14
Cherrington, J.M.15
Mendel, D.B.16
-
20
-
-
3142691273
-
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
-
Berthou S., Aebersold D.M., Schmidt L.S., Stroka D., Heigl C., Streit B., Stalder D., Gruber G., Liang C., Howlet A.R., Candinas D., Greiner R.H., Lipson K.E., and Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23 (2004) 5387-5393
-
(2004)
Oncogene
, vol.23
, pp. 5387-5393
-
-
Berthou, S.1
Aebersold, D.M.2
Schmidt, L.S.3
Stroka, D.4
Heigl, C.5
Streit, B.6
Stalder, D.7
Gruber, G.8
Liang, C.9
Howlet, A.R.10
Candinas, D.11
Greiner, R.H.12
Lipson, K.E.13
Zimmer, Y.14
-
21
-
-
0242268455
-
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a
-
Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R., Rusconi L., and Cristiani C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl. Acad. Sci. USA 100 (2003) 12654-12659
-
(2003)
Proc. Natl. Acad. Sci. USA
, vol.100
, pp. 12654-12659
-
-
Schiering, N.1
Knapp, S.2
Marconi, M.3
Flocco, M.M.4
Cui, J.5
Perego, R.6
Rusconi, L.7
Cristiani, C.8
-
22
-
-
0030945871
-
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
-
Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., and Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276 (1997) 955-960
-
(1997)
Science
, vol.276
, pp. 955-960
-
-
Mohammadi, M.1
McMahon, G.2
Sun, L.3
Tang, C.4
Hirth, P.5
Yeh, B.K.6
Hubbard, S.R.7
Schlessinger, J.8
-
23
-
-
0035400394
-
Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies
-
Miller M., Ginalski K., Lesyng B., Nakaigawa N., Schmidt L., and Zbar B. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 44 (2001) 32-43
-
(2001)
Proteins
, vol.44
, pp. 32-43
-
-
Miller, M.1
Ginalski, K.2
Lesyng, B.3
Nakaigawa, N.4
Schmidt, L.5
Zbar, B.6
-
24
-
-
0030799090
-
Activating mutations for the met tyrosine kinase receptor in human cancer
-
Jeffers M., Schmidt L., Nakaigawa N., Web C.P., Weirich G., Kishida T., Zbar B., and Vande Woude G.F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 11445-11450
-
(1997)
Proc. Natl. Acad. Sci. USA
, vol.94
, pp. 11445-11450
-
-
Jeffers, M.1
Schmidt, L.2
Nakaigawa, N.3
Web, C.P.4
Weirich, G.5
Kishida, T.6
Zbar, B.7
Vande Woude, G.F.8
-
25
-
-
0032569883
-
Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor
-
Jeffers M., Koochekpour S., Fiscella M., Sathyanarayana B.K., and Vande Woude G.F. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. Oncogene 17 (1998) 2691-2700
-
(1998)
Oncogene
, vol.17
, pp. 2691-2700
-
-
Jeffers, M.1
Koochekpour, S.2
Fiscella, M.3
Sathyanarayana, B.K.4
Vande Woude, G.F.5
-
26
-
-
0037075606
-
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met
-
Petrelli A., Gilestro G.F., Lanzardo S., Comoglio P.M., Migone N., and Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416 (2002) 187-190
-
(2002)
Nature
, vol.416
, pp. 187-190
-
-
Petrelli, A.1
Gilestro, G.F.2
Lanzardo, S.3
Comoglio, P.M.4
Migone, N.5
Giordano, S.6
-
27
-
-
3142761786
-
A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation
-
Peschard P., Ishiyama N., Lin T., Lipkowitz S., and Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 279 (2004) 29565-29571
-
(2004)
J. Biol. Chem.
, vol.279
, pp. 29565-29571
-
-
Peschard, P.1
Ishiyama, N.2
Lin, T.3
Lipkowitz, S.4
Park, M.5
-
28
-
-
0034693753
-
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
-
Furge K.A., Zhang Y.W., and Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19 (2000) 5582-5589
-
(2000)
Oncogene
, vol.19
, pp. 5582-5589
-
-
Furge, K.A.1
Zhang, Y.W.2
Vande Woude, G.F.3
-
29
-
-
0032564368
-
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth
-
Bardelli A., Longati P., Gramaglia D., Basilico C., Tamagnone L., Giordano S., Ballinari D., Michieli P., and Comoglio P.M. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc. Natl. Acad. Sci. USA 95 (1998) 14379-14383
-
(1998)
Proc. Natl. Acad. Sci. USA
, vol.95
, pp. 14379-14383
-
-
Bardelli, A.1
Longati, P.2
Gramaglia, D.3
Basilico, C.4
Tamagnone, L.5
Giordano, S.6
Ballinari, D.7
Michieli, P.8
Comoglio, P.M.9
-
30
-
-
0036896226
-
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion
-
Lorenzato A., Olivero M., Patane S., Rosso E., Oliaro A., Comoglio P.M., and Di Renzo M.F. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 62 (2002) 7025-7030
-
(2002)
Cancer Res.
, vol.62
, pp. 7025-7030
-
-
Lorenzato, A.1
Olivero, M.2
Patane, S.3
Rosso, E.4
Oliaro, A.5
Comoglio, P.M.6
Di Renzo, M.F.7
-
31
-
-
0038375012
-
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
-
Corbin A.S., La Rosee P., Stoffregen E.P., Druker B.J., and Deininger M.W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101 (2003) 4611-4614
-
(2003)
Blood
, vol.101
, pp. 4611-4614
-
-
Corbin, A.S.1
La Rosee, P.2
Stoffregen, E.P.3
Druker, B.J.4
Deininger, M.W.5
-
32
-
-
44449151030
-
Drug development of MET inhibitors: targeting oncogene addiction and expedience
-
Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug. Discov. 7 (2008) 504-516
-
(2008)
Nat. Rev. Drug. Discov.
, vol.7
, pp. 504-516
-
-
Comoglio, P.M.1
Giordano, S.2
Trusolino, L.3
-
33
-
-
67649393456
-
MET pathway as a therapeutic target
-
Kim E.S., and Salgia R. MET pathway as a therapeutic target. J. Thorac. Oncol. 4 (2009) 444-447
-
(2009)
J. Thorac. Oncol.
, vol.4
, pp. 444-447
-
-
Kim, E.S.1
Salgia, R.2
|